Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343 · Relapsing-remitting Multiple Sclerosis (RRMS)
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
PhasePhase 3
TypeInterventional
Age18 Years – 99 Years
WhereMobile, Alabama, United States + 108 more
SponsorAmgen
▾Tap for detailsClick for full details — eligibility, all locations, contacts
109 sitesApply